Detalhe da pesquisa
1.
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.
Gynecol Oncol
; 178: 110-118, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37839313
2.
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice.
Am J Hematol
; 98(5): 720-729, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36708469
3.
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
Invest New Drugs
; 40(5): 1042-1050, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35932388
4.
Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
Invest New Drugs
; 39(2): 488-498, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33089874
5.
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Br J Cancer
; 123(11): 1590-1598, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32913286
6.
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
Blood
; 131(13): 1415-1424, 2018 03 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29348128
7.
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Invest New Drugs
; 37(1): 87-97, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29781056
8.
Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies.
Br J Clin Pharmacol
; 85(11): 2568-2579, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31355467
9.
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
Br J Clin Pharmacol
; 85(7): 1464-1473, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30845347
10.
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes.
Haematologica
; 108(4): 1196-1199, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36475522
11.
An oral HemokineTM, α-methylhydrocinnamate, enhances myeloid and neutrophil recovery following irradiation in vivo.
Blood Cells Mol Dis
; 63: 1-8, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27888688
12.
Epigenetic Treatment of Persistent Viral Infections.
Drug Dev Res
; 78(1): 24-36, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27761936
13.
Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms.
Blood Cells Mol Dis
; 56(1): 62-9, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26603726
14.
Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases.
Drug Dev Res
; 77(3): 109-23, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26899010
15.
Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia.
Drug Dev Res
; 77(2): 53-72, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26899191
16.
Bioprotective carnitinoids: lipoic acid, butyrate, and mitochondria-targeting to treat radiation injury: mitochondrial drugs come of age.
Drug Dev Res
; 76(4): 167-75, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26109467
17.
Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.
Blood
; 119(4): 1008-17, 2012 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-22160379
18.
Protein kinase C-δ inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo.
BMC Cancer
; 14: 90, 2014 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24528676
19.
A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?
Leuk Res
; 138: 107465, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38422881
20.
SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells.
Prostate
; 73(5): 522-30, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23038275